Navigation Links
In Relapsed/Refractory Multiple Myeloma, Thought Leaders Are Optimistic that the Combination of Carfilzomib, Lenalidomide and Dexamethasone Will Be the Most Efficacious Regimen
Date:5/14/2013

BURLINGTON, Mass., May 14, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed U.S. and European hematological oncologists indicate that overall survival is the factor that most influences their prescribing decisions for relapsed/refractory multiple myeloma, and that increased overall survival is associated with the highest level of unmet need. Interviewed thought leaders are optimistic that the CRd regimen— carfilzomib (Onyx Pharmaceuticals/Ono Pharmaceutical's Kyprolis) in combination with lenalidomide (Celgene's Revlimid) and dexamethasone—will show advantages over sales-leading lenalidomide plus dexamethasone (the Rd regimen) on this attribute in the ongoing Phase III ASPIRE trial.

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36784LOGO)

The DecisionBase 2013 report entitled As Carfilzomib and Pomalidomide Make Inroads Into the Market, What Key Attributes Will Differentiate Emerging Therapies According to Hematological Oncologists and Payers? finds that surveyed U.S. managed care organization (MCO) pharmacy directors demand that emerging therapies provide significant improvements in overall survival over Rd—a premium-priced standard-of-care regimen for relapsed/refractory multiple myeloma—to justify their cost and secure reimbursement. Notably, half of surveyed payers would not reimburse a new therapy priced the same as Rd or higher that offers a three-month improvement in overall survival over Rd, citing insufficient overall clinical benefit as one of the key reasons for not granting reimbursement.

The report also finds that surveyed U.S. and European hematological oncologists identified neurotoxicity as the safety and tolerability attribute that is most important to prescribing decisions in relapsed/refractory multiple myeloma, thus indicating the persisting high level of unmet need for therapies with a more favorable peripheral neuropathy profile.

"Despite the improvements effected by carfilzomib and the subcutaneous formulation of bortezomib (Takeda/Janssen-Cilag/Janssen's Velcade) on the incidence of peripheral neuropathy associated with standard intravenous bortezomib, our survey results suggest that further improvement in neurotoxicity remains a key opportunity for product differentiation," said Decision Resources Senior Business Insights Analyst Khurram Nawaz , M.Sc. "Early-stage clinical data suggest that the oral proteasome inhibitor MLN9708 (Takeda/Millennium) is associated with little peripheral neuropathy. MLN9708 has the potential to gain a competitive edge over currently available proteasome inhibitors if it can replicate these promising results in its ongoing Phase III trial, provided it is at least as efficacious as bortezomib and carfilzomib."

About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

 


'/>"/>
SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Follow-up Results of Phase 2 Study of Investigational Agent, Ibrutinib, in Relapsed/Refractory Mantle Cell Lymphoma Presented at American Society of Hematology Annual Meeting
2. Follow-up Results of Phase 2 Study of Investigational Agent, Ibrutinib, Suggest High and Durable Responses in Relapsed/Refractory Mantle Cell Lymphoma
3. Hobart Group Holdings Marks 10th Anniversary With Multiple Milestones
4. Mapi Pharma Granted United States Patent Covering Glatiramer Depot for Multiple Sclerosis
5. For Pharma Companies, Launching Multiple Similar Products Can Be a "Good Problem" but Requires Smart Resourcing
6. Deploying an Effective Pay for Performance Bonus System that Works Across Multiple Industry Sectors
7. Aurigene Announces Transition of Multiple Programs to Clinical Development in its Collaboration Business
8. Omeros Announces that GPR17 Antagonists Improve Function in Model of Multiple Sclerosis
9. Surveyed U.S. Neurologists Would Prescribe Biogen Idecs Tecfidera to 20 Percent of Their Patients with Relapsing-Remitting Multiple Sclerosis (RR-MS)
10. Star Scientific, Inc. Issues Statement in Response to Two Plaintiffs Purported Class Action Law Suits and Multiple Press Releases Issued by Plaintiffs Law Firms Trolling for New Clients
11. MedNet Solutions To Participate In Multiple Clinical Research Conferences In April 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/16/2017)... DaVita Inc. (NYSE: DVA ) today ... 2016. Net income attributable to DaVita Inc. ... $158 million, or $0.80 per share and $880 million, or ... attributable to DaVita Inc. for the quarter and year ended ... $192 million, or $0.98 per share, and $789 million, or ...
(Date:2/16/2017)... -- Newly published research from the CVS Health (NYSE: ... private retailer can play in restricting access to tobacco ... in the American Journal of Public Health , ... all CVS Pharmacy stores reduced the number of cigarette ... impact on those who bought cigarettes exclusively at CVS ...
(Date:2/16/2017)... 16, 2017  Prescription pain medications provided by "physicians ... necessary for long-term opioid use to take hold," according ... edition of The New England Journal of ... more patients in acute pain than in almost any ... FACEP, president of the American College of Emergency Physicians. ...
Breaking Medicine Technology:
(Date:2/18/2017)... Dallas, Texas (PRWEB) , ... February 17, 2017 , ... ... Arden Moore’s “Oh Behave” Show on the Pet Life Radio network. The episode, ... explores a number of topics including: what factors led to Park Cities Pet Sitter’s ...
(Date:2/17/2017)... CA (PRWEB) , ... February 17, 2017 , ... ... focus on foundational and sustainable systems change designed to further positively impact the ... “The Board of Trustees has long considered it our duty to seriously consider ...
(Date:2/17/2017)... ... February 17, 2017 , ... Corrective ... Warning Letter, **An FDAnews Webinar**, Feb. 23, 2017 — 1:30 p.m. – 3:00 ... corrective action (CA) and preventive action (PA)? , The methods share techniques and ...
(Date:2/17/2017)... ... February 17, 2017 , ... Pharmica Consulting attended CHI's ... facets of clinical trial planning and management. Pharmica discussed the importance of effective ... addition, attendees stopping by Pharmica’s booth were able to demo its cloud-based ...
(Date:2/17/2017)... ... 2017 , ... The Mason Pasquin Agency, a Virginia-based firm ... in and around the Hampton Roads metropolitan region, is joining the local nonprofit ... violence. , There are multiple categories of domestic violence – physical abuse is ...
Breaking Medicine News(10 mins):